Pilot Trial Investigating Fermented Whey Supplementation in Healthy Adults
The Use of Fermented Whey Concentrate in Healthy Adults
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Aberdeen, United Kingdom, AB25 2ZD
- The Rowett Institute, Human Nutrition Unit
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age 18-65
- BMI 18-40 kg/m-2
Exclusion Criteria:
- Diabetes
- Severe gastrointestinal disorders,
- Kidney disease,
- Thromboembolic or coagulation disease,
- Hepatic disease,
- Alcohol or any other substance abuse
- Gout
- Eating disorders
- Unregulated thyroid disease
- Dairy intolerance
- Antibiotic use within the last 3 months, including prescribed use
- Current prebiotic or prebiotic use
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Molkosan
Consumption of Molkosan (fermented whey) 20ml to be diluted in 200ml water prior to use twice a day (morning & evening). Total duration was 6 weeks. |
Twice daily (AM and PM) 20ml of fermented whey concentrate consumed diluted in 200ml water
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in microbiota activity
Time Frame: Baseline, day 21 and 42
|
Faecal short-chain fatty acids, measured by gas chromatography
|
Baseline, day 21 and 42
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in glucose tolerance (Oral glucose tolerance test (OGTT)
Time Frame: Baseline, day 21 and 42
|
Six blood samples will be collected during the course of 3 hours (0, 30, 60, 90,120 and 180 min) using a cannulation after consuming 75 g of Polycal liquid (glucose load).
Plasma glucose level and insulin are analysed as total area under the curve (AUC) and incremental AUC.
|
Baseline, day 21 and 42
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in microbiota composition - 16s rRNA (ribosomal ribonucleic acid) sequencing
Time Frame: Baseline, day 21 and 42
|
16S rRNA extracted from fresh stool samples (<16hrs)
|
Baseline, day 21 and 42
|
|
Subjective assessment of digestion and bowel movements
Time Frame: Baseline and day 14-18
|
Volunteer self-reported symptoms measured by questionnaire
|
Baseline and day 14-18
|
|
Energy intake
Time Frame: Baseline and day 14-18
|
4-day weighed food diary analysed for energy intake and macronutrient composition
|
Baseline and day 14-18
|
|
Blood pressure
Time Frame: Screening, baseline and day 42
|
Repeated in triplicate, measured in mmHg
|
Screening, baseline and day 42
|
|
Pulse
Time Frame: Screening, baseline and day 42
|
Triplicate measurement, expressed as beats per minute
|
Screening, baseline and day 42
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Alexandra M Johnstone, Ph.D, Rowett Institute, University of Aberdeen
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 799
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.